The big intestine is where colon cancer typically first manifests itself (colon). The digestive system ends with the colon. Colon cancer can strike anyone at any age, but it often strikes older persons. Small, benign (noncancerous) cell clusters called polyps commonly grow on the interior of the colon as the first signs of the condition. Some of these polyps may eventually develop into colon cancer.
Access Full Report at https://www.databridgemarketresearch.com/fr/reports/asia-pacific-colorectal-cancer-diagnostics-market
People affected with colorectal cancer can see the symptoms such as a persistent change in bowel habits, including diarrhea or constipation or a change in the consistency of the stool, rectal bleeding or blood in the stool, persistent abdominal discomfort, such as cramps, gas or pain, a feeling that the bowel doesn't empty completely, weakness or fatigue, unexplained weight loss.
Data Bridge Market Research analyses that the Asia-Pacific Colorectal Cancer Diagnostics Market is expected to grow at a CAGR of 9.0% in the forecast period of 2023 to 2030 and is expected to reach USD 1,056,573.99 thousand by 2030. The instruments are projected to propel the market's growth as they are widely used for diagnosis in various regions, and more advanced technologies are available. Especially these instruments have a broad range of applications for research and clinical purposes, including cancer diagnosis, chromosome identification, and protein expression.
Key Findings of the Study
Growing Prevalence of Colorectal Cancer
Colorectal cancer is sometimes called colon cancer, which is a term that combines colon cancer and rectal cancer, which begins in the rectum. Colon cancer typically affects older adults, though it can happen at any age. It usually begins as small, noncancerous (benign) clumps of cells called polyps forming inside the colon. Over time some of these polyps can become colon cancers.
People affected with colorectal cancer can see the symptoms such as a persistent change in bowel habits, including diarrhea or constipation or a change in the consistency of the stool, rectal bleeding or blood in the stool, persistent abdominal discomfort, such as cramps, gas or pain, a feeling that the bowel doesn't empty, weakness or fatigue, and unexplained weight loss.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Test Type (Stool Examination, Imaging Test, Biopsy, Blood Test, and Others), Product Type (Instruments and Kits and Reagents), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, leiomyosarcomas, melanomas, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales and Online Sales)
|
|
Countries Covered
|
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN(U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated, Inc. (U.S.), Siemens Healthcare GmbH (Germany), Myriad Genetics, Inc. (U.S.), Koninklijke Philips N.V. (Netherland), FUJIFILM Corporation (Japan), CANON MEDICAL SYSTEMS CORPORATION (Japan), Bio-Rad Laboratories, Inc. (U.S.), Neusoft Corporation (China), Exact Sciences Corporation(U.S.), bioMérieux SA (France), Sysmex Asia Pacific Pte Ltd (Singapore), GE HealthCare(U.S.), Medtronic(Ireland) and Agilent Technologies, Inc. (U.S.), among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The Asia-Pacific colorectal cancer diagnostics market is segmented based on test type, product type, cancer stages, age group, cancer type, end user, and distribution channel.
- On the basis of test type, the Asia-Pacific colorectal cancer diagnostic market is segmented into stool examination, imaging tests, biopsy, blood tests, and others.
In 2023, the stool examination segment is expected to dominate the Asia-Pacific colorectal cancer diagnostic market
In 2023, the stool examination segment is expected to dominate the market with a 49.09% market share as this type of procedure is widely popular, and patients are aware of this procedure.
- On the basis of product type, the Asia-Pacific colorectal cancer diagnostics market is segmented into instruments and kits and reagents.
In 2023, the instruments segment is expected to dominate the Asia-Pacific colorectal cancer diagnostic market
In 2023, the instruments segment is expected to dominate the market with a 69.63% market share as these products are utilized in various regions, and more advanced technologies are available.
- On the basis of cancer stages, the Asia-Pacific colorectal cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III, and stage IV. In 2023, the stage III segment is expected to dominate the Asia-Pacific colorectal cancer diagnostics market with a 43.02% market share.
- On the basis of age group, the Asia-Pacific colorectal cancer diagnostics market is segmented into geriatric, adults, and pediatric. In 2023, the geriatric segment is expected to dominate the Asia-Pacific colorectal cancer diagnostics market with a 49.33% market share.
- On the basis of cancer type, the Asia-Pacific colorectal cancer diagnostics market is segmented into adenocarcinoma, colorectal lymphoma, gastrointestinal stromal tumors, carcinoid tumors, leiomyosarcomas, melanomas, and others. In 2023, the adenocarcinoma segment is expected to dominate the Asia-Pacific colorectal cancer diagnostics market with a 51.70% market share.
- On the basis of end user, the Asia-Pacific colorectal cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, Ambulatory Surgical Center, academic institutes, and others. In 2023, the hospital segments are expected to dominate the Asia-Pacific colorectal cancer diagnostics market with a 34.99% market share.
- On the basis of distribution channel, the Asia-Pacific colorectal cancer diagnostic market is segmented into direct tender, retail sales, and online sales. In 2023, the direct tender segment is expected to dominate the Asia-Pacific colorectal cancer diagnostics market with a 56.94% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the major players in Asia-Pacific colorectal cancer diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (U.S.), QIAGEN(U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated, Inc. (U.S.), Siemens Healthcare GmbH (Germany), Myriad Genetics, Inc. (U.S.), Koninklijke Philips N.V. (Netherland), FUJIFILM Corporation (Japan), CANON MEDICAL SYSTEMS CORPORATION (Japan), Bio-Rad Laboratories, Inc. (U.S.), Neusoft Corporation (China), Exact Sciences Corporation(U.S.), bioMérieux SA (France), Sysmex Asia Pacific Pte Ltd (Singapore), GE HealthCare(U.S.), Medtronic(Ireland) and Agilent Technologies, Inc. (U.S.), among others.
Market Development
- In November 2022, Canon Inc. acquired Redlen Technologies Inc. (Redlen), one of the world's leading companies in creating new technologies related to developing and manufacturing semiconductor detector modules1. Canon Medical Systems Corporation (Canon Medical), a company of Canon Inc., has developed the first domestically produced 2 photon-counting CT (PCCT)3 system incorporating Redlen's advanced technologies. This system has been installed at the National Cancer Centre (NCC) Exploratory Oncology Research & Clinical Trial Centre in Japan, where it is currently used to research the clinical applications of PCCT.
- In October 2022, Koninklijke Philips N.V. announced the imaging and simulation of head and neck cancer radiation had advanced thanks to two significant developments in MR-only workflows. In the company's artificial intelligence-enabled MRCAT radiation application, soft tissue tumors of the head and neck and those of the brain, pelvis, and prostate can be treated using MRI as the primary imaging modality for planning. The device has been given FDA 510(k) clearance and is offered for sale in the United States. This helps the company to increase its global presence of the company as well as helps in revenue expansion.
- In October 2022, Thermo Fisher Scientific Inc., announced that it is going to expand its laboratory operations in Highland Heights, Kentucky, helping customers deliver life-changing medicines to patients. The current facility, which includes central lab and biomarker operations, provides biopharma customers with high-quality laboratory services to accelerate drug development. This has helped the company to expand its clinical diagnostics business across various regions in the world and helped to increase the global presence in the market.
- In August 2022, Bio-Rad Laboratories Inc. completed its acquisition of Curiosity Diagnostics which is a Poland based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and global presence in the market.
- In May 2022, F. Hoffmann-La Roche Ltd has totally acquired Stratos Genomics officially. With this acquisition, the company will also deal with the development of DNA sequencing for diagnostics use. This has enhanced the healthcare diagnosis segment of the company, thus leading to more revenue generation for the company.
Regional Analysis
Geographically, the countries covered in the Asia-Pacific colorectal cancer diagnostics market report are China, India, Japan, South Korea, Thailand, Singapore, Indonesia, Malaysia, Philippines, Australia, Vietnam and Rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
China is the dominating and fastest growing country in the Asia-Pacific colorectal cancer diagnostics market during the forecast period 2023 - 2030
China dominated the Asia-Pacific colorectal cancer diagnostics market and be a fastest growing country owing to the higher level of investments by manufacturers and the increasing prevalence of cancer diagnostics.
COVID-19 Impact Analysis
The outbreak of COVID-19 largely impacted the healthcare industry. The advanced wound care market was, however adversely affected by it. The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to the emergence of various challenges such as the denied diagnostics centers, canceled or postponed diagnostic treatment, stifling business growth, suspensions of new developments and even increasing cases in COVID-19 medical care providers, further limiting the industry's expansion. As the admission of COVID-19 patients in hospitals increased, numerous cancer diagnostics were canceled or postponed to reserve hospital beds and patient care staff to COVID-19 patient care. Developing and implementing contingency plans is highly crucial for business operations and key imported raw materials.
On the brighter side, there has been a decline in COVID-19 patients worldwide, which will result in increased cancer care services. Moreover, the restrictions and measures are likely to relax, which will help market to witness a slight increment, as the manufacturers are focusing on various developments and innovations, market trends, and other expansion strategies. Thus, Asia-Pacific colorectal cancer diagnostics market will grow at an accelerated pace post COVID-19.
For more detailed information about the Asia-Pacific colorectal cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/fr/reports/asia-pacific-colorectal-cancer-diagnostics-market
